

# Hongzhou Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1950340/publications.pdf>

Version: 2024-02-01

132  
papers

8,280  
citations

212478

28  
h-index

62345

84  
g-index

139  
all docs

139  
docs citations

139  
times ranked

18377  
citing authors

#	ARTICLE	IF	CITATIONS
1	HIV/AIDS strategies should focus on outcomes and the psychological status of older patients diagnosed with HIV. <i>BioScience Trends</i> , 2022, 16, 91-98.	1.1	3
2	SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network. <i>EBioMedicine</i> , 2022, 76, 103861.	2.7	24
3	Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0205721.	1.4	6
4	Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 91.	7.1	14
5	Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses. <i>Cell Discovery</i> , 2022, 8, 36.	3.1	22
6	Concerns of Parental HIV Disclosure in China. <i>Clinical Nursing Research</i> , 2021, 30, 830-839.	0.7	4
7	The role of peripheral blood eosinophil counts in COVID-19 patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 471-482.	2.7	131
8	Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1670-1678.	1.4	13
9	Shufeng Jiedu, a promising herbal therapy for moderate COVID-19: Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. <i>Phytomedicine</i> , 2021, 85, 153390.	2.3	60
10	Pathogenesis-directed therapy of 2019 novel coronavirus disease. <i>Journal of Medical Virology</i> , 2021, 93, 1320-1342.	2.5	40
11	Correlation Between Early Plasma Interleukin 37 Responses With Low Inflammatory Cytokine Levels and Benign Clinical Outcomes in Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 223, 568-580.	1.9	17
12	Disclosure experience among COVID-19-confirmed patients in China: A qualitative study. <i>Journal of Clinical Nursing</i> , 2021, 30, 783-792.	1.4	18
13	CCL28 mucosal expression in SARS-CoV-2-infected patients with diarrhea in relation to disease severity. <i>Journal of Infection</i> , 2021, 82, e19-e21.	1.7	11
14	Update: Drug treatment options for coronavirus disease 2019 (COVID-19). <i>BioScience Trends</i> , 2021, 15, 345-349.	1.1	5
15	A streamlined clinical metagenomic sequencing protocol for rapid pathogen identification. <i>Scientific Reports</i> , 2021, 11, 4405.	1.6	15
16	A deep learning-based quantitative computed tomography model for predicting the severity of COVID-19: a retrospective study of 196 patients. <i>Annals of Translational Medicine</i> , 2021, 9, 216-216.	0.7	44
17	Epigenetic Landscapes of Single-Cell Chromatin Accessibility and Transcriptomic Immune Profiles of T Cells in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 625881.	2.2	30
18	Vitamin C supplementation is necessary for patients with coronavirus disease: An ultra-high-performance liquid chromatography-tandem mass spectrometry finding. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 196, 113927.	1.4	23

#	ARTICLE	IF	CITATIONS
19	New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals. <i>BioScience Trends</i> , 2021, 15, 126-128.	1.1	32
20	Burnout in nurses during the COVID-19 pandemic in China: New challenges for public health. <i>BioScience Trends</i> , 2021, 15, 129-131.	1.1	9
21	Combating COVID-19 as a designated hospital: Experience from Shanghai, China. <i>Global Health &amp; Medicine</i> , 2021, 3, 112-114.	0.6	1
22	Post-Traumatic Growth Experiences among COVID-19 Confirmed Cases in China: A Qualitative Study. <i>Clinical Nursing Research</i> , 2021, 30, 1079-1087.	0.7	34
23	Case report: histopathology and molecular pathology analysis on enteric tissue of a COVID-19 patient. <i>Diagnostic Pathology</i> , 2021, 16, 40.	0.9	3
24	Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 568789.	2.2	9
25	Clinical usefulness of metagenomic next-generation sequencing for the diagnosis of central nervous system infection in people living with HIV. <i>International Journal of Infectious Diseases</i> , 2021, 107, 139-144.	1.5	14
26	Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. <i>Cell Discovery</i> , 2021, 7, 42.	3.1	23
27	Simultaneous determination of first-line anti-tuberculosis drugs and one metabolite of isoniazid by liquid chromatography/tandem mass spectrometry in patients with human immunodeficiency virus-tuberculosis coinfection. <i>Heliyon</i> , 2021, 7, e07532.	1.4	5
28	Resilience of frontline nurses during the COVID-19 pandemic in China: A qualitative study. <i>Australian Journal of Cancer Nursing</i> , 2021, 23, 639-645.	0.8	23
29	HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo. <i>Frontiers in Microbiology</i> , 2021, 12, 684016.	1.5	15
30	Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19. <i>BioScience Trends</i> , 2021, 15, 205-210.	1.1	8
31	FKBP3 Induces Human Immunodeficiency Virus Type 1 Latency by Recruiting Histone Deacetylase 1/2 to the Viral Long Terminal Repeat. <i>MBio</i> , 2021, 12, e0079521.	1.8	4
32	Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1711-1724.	1.1	1
33	Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals. <i>Cell Discovery</i> , 2021, 7, 89.	3.1	27
34	Incidence and spectrum of infections among HIV/AIDS patients with lymphoma during chemotherapy. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1459-1464.	0.8	10
35	Therapeutic Monitoring of Plasma Digoxin for COVID-19 Patients Using a Simple UPLC-MS/MS Method. <i>Current Pharmaceutical Analysis</i> , 2021, 17, 1308-1316.	0.3	2
36	Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody. <i>Emerging Microbes and Infections</i> , 2021, 10, 1638-1648.	3.0	13

#	ARTICLE	IF	CITATIONS
37	The predictive role of lymphocyte subsets and laboratory measurements in COVID-19 disease: a retrospective study. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110497.	1.0	8
38	Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2pos subjects. <i>Cell Research</i> , 2021, 31, 1148-1162.	5.7	12
39	Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. <i>Genome Medicine</i> , 2021, 13, 164.	3.6	42
40	Saliva specimen complements anal swab in assessing patients with COVID-19 for discharge from hospital. <i>Emerging Microbes and Infections</i> , 2021, 10, 2090-2097.	3.0	1
41	Risk factors for myocardial injury at admission of 325 patients with coronavirus disease 2019 in Shanghai, China. <i>Australasian Journal on Ageing</i> , 2021, , .	0.4	3
42	Longitudinal trajectory of the association between quality of life and depression among people living with HIV in China: a mixed effects model. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-8.	0.6	1
43	Simultaneously Determining Seven Second-Line Anti-TB Drugs by UHPLC-MS: Application for TDM in HIV-TB Patients. <i>Current Pharmaceutical Analysis</i> , 2021, 18, .	0.3	0
44	Editing out HIV: application of gene editing technology to achieve functional cure. <i>Retrovirology</i> , 2021, 18, 39.	0.9	7
45	Tobacco use and HIV symptom severity in Chinese people living with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 217-222.	0.6	10
46	Self-Management Behaviors Among Patients With Liver Cirrhosis in Shanghai, China: A Cross-Sectional Study. <i>Clinical Nursing Research</i> , 2020, 29, 448-459.	0.7	11
47	An open-label, randomized trial of the combination of IFN- $\beta$ plus TFF2 with standard care in the treatment of patients with moderate COVID-19. <i>EClinicalMedicine</i> , 2020, 27, 100547.	3.2	29
48	Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. <i>Emerging Microbes and Infections</i> , 2020, 9, 1988-1996.	3.0	58
49	Clinical characteristics in patients with SARS-CoV-2/HBV co-infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1504-1507.	1.0	56
50	PEBP 1 suppresses HIV transcription and induces latency by inactivating MAPK / NF- $\kappa$ B signaling. <i>EMBO Reports</i> , 2020, 21, e49305.	2.0	21
51	Prediction of COVID-19 Patients at High Risk of Progression to Severe Disease. <i>Frontiers in Public Health</i> , 2020, 8, 574915.	1.3	15
52	A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN- $\beta$ plus TFF2 in patients with moderate COVID-19. <i>EClinicalMedicine</i> , 2020, 25, 100478.	3.2	20
53	Mycobacterium tuberculosis co-infection is associated with increased surrogate marker of the HIV reservoir. <i>AIDS Research and Therapy</i> , 2020, 17, 63.	0.7	6
54	Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China. <i>Pharmacogenomics</i> , 2020, 21, 945-956.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. <i>JAMA Internal Medicine</i> , 2020, 180, 1356.	2.6	211
56	CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. <i>Theranostics</i> , 2020, 10, 5613-5622.	4.6	166
57	Use of comedications and potential drug-drug interactions in people living with HIV in China. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 722-728.	0.8	6
58	&lt;p&gt;Discovery of Potential Plasma Biomarkers for Tuberculosis in HIV-Infected Patients by Data-Independent Acquisition-Based Quantitative Proteomics&lt;/p&gt;. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 1185-1196.	1.1	4
59	Clinical Potential of <sc>UTEâ€MRI</sc> for Assessing <sc>COVID</sc>â€19: Patientâ€and Lesionâ€Based Comparative Analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 397-406.	1.9	48
60	Epidemiology and clinical course of COVID-19 in Shanghai, China. <i>Emerging Microbes and Infections</i> , 2020, 9, 1537-1545.	3.0	24
61	Viral and host factors related to the clinical outcome of COVID-19. <i>Nature</i> , 2020, 583, 437-440.	13.7	746
62	Quantitative Proteomics Analysis of Systemic Responses and Biological Mechanisms of ShuFengJieDu Capsule Using H1N1-Infected RAW264.7 Cells. <i>ACS Omega</i> , 2020, 5, 15417-15423.	1.6	6
63	Observations about symptomatic and asymptomatic infections of 494 patients with COVID-19 in Shanghai, China. <i>American Journal of Infection Control</i> , 2020, 48, 1045-1050.	1.1	28
64	Effect of combination antiretroviral therapy on the clinical manifestations, radiological characteristics, and disease severity of HIV-associated <i>Talaromyces marneffe</i> infection. <i>International Journal of STD and AIDS</i> , 2020, 31, 747-752.	0.5	3
65	The Wuhan SARSâ€CoVâ€2â€”What's next for China. <i>Journal of Medical Virology</i> , 2020, 92, 546-547.	2.5	51
66	Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. <i>Journal of Medical Virology</i> , 2020, 92, 401-402.	2.5	2,395
67	Drug treatment options for the 2019-new coronavirus (2019-nCoV). <i>BioScience Trends</i> , 2020, 14, 69-71.	1.1	852
68	Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. <i>Radiology</i> , 2020, 295, 210-217.	3.6	997
69	An evolving approach to the laboratory assessment of COVIDâ€19. <i>Journal of Medical Virology</i> , 2020, 92, 1812-1817.	2.5	20
70	Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. <i>BioScience Trends</i> , 2020, 14, 285-289.	1.1	86
71	Clinical and CT features of early stage patients with COVID-19: a retrospective analysis of imported cases in Shanghai, China. <i>European Respiratory Journal</i> , 2020, 55, 2000407.	3.1	48
72	Heterogeneous <i>Klebsiella pneumoniae</i> Co-infections Complicate Personalized Bacteriophage Therapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 608402.	1.8	26

#	ARTICLE	IF	CITATIONS
73	A simple algorithm helps early identification of SARS-CoV-2 infection patients with severe progression tendency. <i>Infection</i> , 2020, 48, 577-584.	2.3	25
74	Unmet needs of symptom management and associated factors among the HIV-positive population in Shanghai, China: A cross-sectional study. <i>Applied Nursing Research</i> , 2020, 54, 151283.	1.0	11
75	Comprehensive Treatment and Management of COVID-19: Expert Consensus Statement from Shanghai. , 2020, , 226-244.		8
76	Analysis of liver injury factors in 332 patients with COVID-19 in Shanghai, China. <i>Aging</i> , 2020, 12, 18844-18852.	1.4	14
77	The development of a quarantine strategy is an important path to a normalized response to COVID-19. <i>BioScience Trends</i> , 2020, 14, 396-398.	1.1	2
78	Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19. <i>BioScience Trends</i> , 2020, 14, 161-167.	1.1	8
79	Proteomic study of the mechanism of talin-C as an inhibitor of HIV infection. <i>Current Proteomics</i> , 2020, 18, .	0.1	0
80	Immediate antiviral therapy for HIV-infected persons faces with various obstacles. <i>Drug Discoveries and Therapeutics</i> , 2019, 13, 172-174.	0.6	3
81	Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections. <i>Antiviral Research</i> , 2019, 169, 104555.	1.9	19
82	The epidemic of major sexually transmitted diseases in Shanghai, China, 2009-2018. <i>BioScience Trends</i> , 2019, 13, 273-275.	1.1	1
83	Characteristics of Gut Microbiota in Patients With Rheumatoid Arthritis in Shanghai, China. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 369.	1.8	117
84	Prevention of mother-to-child transmission (PMTCT) continues to play a vital role in the response to HIV/AIDS: Current status and future perspectives. <i>BioScience Trends</i> , 2019, 13, 107-109.	1.1	2
85	Plasma Membrane Proteomic Profile Discovers Macrophage-capping Protein Related to Latent HIV-1. <i>Current HIV Research</i> , 2019, 17, 42-52.	0.2	6
86	Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients. <i>International Journal of Infectious Diseases</i> , 2019, 83, 64-71.	1.5	11
87	Challenges to eliminating the AIDS pandemic in China. <i>Global Health &amp; Medicine</i> , 2019, 1, 16-19.	0.6	3
88	Evaluation of Epstein-Barr Virus Salivary Shedding in HIV/AIDS Patients and HAART Use: A Retrospective Cohort Study. <i>Virologica Sinica</i> , 2018, 33, 227-233.	1.2	11
89	A structural equation model of patient-healthcare provider relationships and HIV-infected patient outcomes in Chinese populations. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 383-390.	0.6	16
90	The Development of a Brief Distress Reduction Intervention for Individuals Recently Diagnosed With HIV in China. <i>Cognitive and Behavioral Practice</i> , 2018, 25, 319-334.	0.9	6

#	ARTICLE	IF	CITATIONS
91	Reducing distress and promoting resilience: a preliminary trial of a CBT skills intervention among recently HIV-diagnosed MSM in China. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, S39-S48.	0.6	32
92	HIV/AIDS responses in China should focus on the impact of global integration. <i>BioScience Trends</i> , 2018, 12, 507-509.	1.1	12
93	The importance of non-tuberculous mycobacteria identification in Chinese patients infected with HIV. <i>BioScience Trends</i> , 2018, 12, 515-516.	1.1	6
94	Characteristics and Outcomes of <i>Acinetobacter baumannii</i> Infections in Patients with HIV: A Matched Case-Control Study. <i>Scientific Reports</i> , 2018, 8, 15617.	1.6	2
95	Quality of life in HIV-infected Chinese women and their family caregivers: an intervention study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1572-1579.	0.6	10
96	Changes in intestinal microbiota in HIV-1-infected subjects following cART initiation: influence of CD4+ T cell count. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-4.	3.0	39
97	Substance use, anxiety, and self-management efficacy in HIV-positive individuals: A mediation analysis. <i>Journal of Substance Use</i> , 2018, 23, 408-414.	0.3	8
98	Zinc-Finger Nucleases Induced by HIV-1 Tat Excise HIV-1 from the Host Genome in Infected and Latently Infected Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 12, 67-74.	2.3	13
99	Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer. <i>BioScience Trends</i> , 2018, 12, 298-308.	1.1	25
100	Gut Microbiota Dysbiosis Is Not Independently Associated With Neurocognitive Impairment in People Living With HIV. <i>Frontiers in Microbiology</i> , 2018, 9, 3352.	1.5	19
101	Clinicopathologic characteristics of HIV/AIDS-related plasmablastic lymphoma. <i>International Journal of STD and AIDS</i> , 2017, 28, 380-388.	0.5	6
102	Genome-wide screening for highly discriminative SNPs for personal identification and their assessment in world populations. <i>Forensic Science International: Genetics</i> , 2017, 28, 118-127.	1.6	19
103	Trends in baseline CD4 cell counts and risk factors for late antiretroviral therapy initiation among HIV-positive patients in Shanghai, a retrospective cross-sectional study. <i>BMC Infectious Diseases</i> , 2017, 17, 285.	1.3	14
104	Recent 5-year Findings and Technological Advances in the Proteomic Study of HIV-associated Disorders. <i>Genomics, Proteomics and Bioinformatics</i> , 2017, 15, 110-120.	3.0	9
105	iTRAQ based investigation of plasma proteins in HIV infected and HIV/HBV coinfecting patients: C9 and KLK are related to HIV/HBV coinfection. <i>International Journal of Infectious Diseases</i> , 2017, 63, 64-71.	1.5	6
106	Malignancies in HIV-Infected and AIDS Patients. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1018, 167-179.	0.8	42
107	Reactivation of HIV-1 from Latency by an Ingenol Derivative from <i>Euphorbia Kansui</i> . <i>Scientific Reports</i> , 2017, 7, 9451.	1.6	40
108	BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency. <i>Scientific Reports</i> , 2017, 7, 16646.	1.6	37



#	ARTICLE	IF	CITATIONS
109	Clinical and prognostic analysis of 78 patients with human immuno-deficiency virus associated non-Hodgkin's lymphoma in Chinese population. <i>Infectious Agents and Cancer</i> , 2017, 12, 7.	1.2	12
110	Caspase-1 Activity in CD4 T Cells Is Downregulated Following Antiretroviral Therapy for HIV-1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 164-171.	0.5	20
111	A promising magnetic SERS immunosensor for sensitive detection of avian influenza virus. <i>Biosensors and Bioelectronics</i> , 2017, 89, 906-912.	5.3	89
112	Increased MMAB level in mitochondria as a novel biomarker of hepatotoxicity induced by Efavirenz. <i>PLoS ONE</i> , 2017, 12, e0188366.	1.1	2
113	Latest advances in the efficacy, tolerability, and monotherapy of integrase inhibitors. <i>BioScience Trends</i> , 2017, 11, 490-495.	1.1	6
114	An analysis of drug resistance among people living with HIV/AIDS in Shanghai, China. <i>PLoS ONE</i> , 2017, 12, e0165110.	1.1	25
115	The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells. <i>Oncotarget</i> , 2017, 8, 94104-94116.	0.8	9
116	Clinical Characteristics and Prognosis of Penicilliosis Among Human Immunodeficiency Virus-Infected Patients in Eastern China. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 1350-1354.	0.6	31
117	The Development of Criteria for the Selection of Chinese Peer Educators in HIV Management: A Delphi Study. <i>Scientifica</i> , 2016, 2016, 1-4.	0.6	3
118	Fecal bacterial microbiome diversity in chronic HIV-infected patients in China. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-7.	3.0	82
119	The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb. <i>Scientific Reports</i> , 2016, 6, 24100.	1.6	56
120	<i>Editorial Commentary</i> : Control of HIV for Men Who Have Sex With Men in China: A Role for the Internet?. <i>Clinical Infectious Diseases</i> , 2016, 62, 1448-1449.	2.9	0
121	A Mixed-Methods Study Supporting a Model of Chinese Parental HIV Disclosure. <i>AIDS and Behavior</i> , 2016, 20, 165-173.	1.4	20
122	China takes an active role in combating an Ebola outbreak: On-site observations and reflections from a Chinese healthcare provider. <i>Intractable and Rare Diseases Research</i> , 2015, 4, 217-219.	0.3	7
123	Reasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort Analysis. <i>PLoS ONE</i> , 2015, 10, e0133242.	1.1	4
124	Extra-pulmonary viral shedding in H7N9 Avian Influenza patients. <i>Journal of Clinical Virology</i> , 2015, 69, 30-32.	1.6	28
125	Two cellular microRNAs, miR-196b and miR-1290, contribute to HIV-1 latency. <i>Virology</i> , 2015, 486, 228-238.	1.1	34
126	Vimentin&mdash;a potential biomarker for therapeutic efficiency of HAART. <i>Acta Biochimica Et Biophysica Sinica</i> , 2014, 46, 1001-1006.	0.9	5



#	ARTICLE	IF	CITATIONS
127	Anti-Retroviral Therapy Decreases but Does Not Normalize Indoleamine 2,3-Dioxygenase Activity in HIV-Infected Patients. PLoS ONE, 2014, 9, e100446.	1.1	40
128	An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China. Chinese Medical Journal, 2014, 127, 59-65.	0.9	16
129	Discovery process, clinical characteristics, and treatment of patients infected with avian influenza virus (H7N9) in Shanghai. Chinese Medical Journal, 2014, 127, 185-6.	0.9	3
130	Human infection with avian influenza A(H7N9) virus in Shanghai: current status and future trends. Chinese Medical Journal, 2014, 127, 1973-6.	0.9	1
131	2014 update of the Chinese guidelines for diagnosis and treatment of avian influenza A(H7N9) virus infection. Chinese Medical Journal, 2014, 127, 2543-7.	0.9	4
132	Population pharmacokinetics and model-informed precision dosing of lamivudine in Chinese HIV-infected patients with mild and moderate impaired renal function. Expert Review of Clinical Pharmacology, 0, , 1-9.	1.3	0